The Impact of Chemical Toxicants and Air Pollutants on Neurodegenerative Disorders and Their Underlying Potential Mechanisms: A Literature Review Authors: Sameeha Fatima Khan, Warda Rasool, Muhammad Hamza Khan, Ganesh Kumar, Azka Ijaz, Maryam Amjad, Mahin Qudeer Sheikh, Shree Rath, Digbijay Kunwar, Anum Akbar Published: 2026 ABSTRACT ABSTRACTBackground and AimsNeurodegenerative disorders are marked by progressive deterioration of neurons, affecting cognitive, memory, and motor functions. This decline creates substantial personal and social challenges, making early identification of risk factors essential for effective intervention. Environmental toxicants, such as chemicals and air pollutants, are suspected to negatively impact brain health. This review critically examines the relationship between environmental toxicants and neurodegenerative disorders, exploring their potential mechanisms and providing recommendations for future research.MethodsA PubMed search was performed for all available data until April 2024 using keywords related to environmental toxicants and neurodegenerative diseases. The search was limited to peer‐reviewed articles in English, focusing on human studies that investigate the association between toxicants and neurodegenerative disorders. A narrative synthesis was conducted based on the neurodegenerative disorder, specific toxicants, and mechanisms of action.ResultsThis review highlights the detrimental effects of chemical toxicants and air pollutants on diseases, such as Parkinson's, Alzheimer's, multiple sclerosis, and Huntington's disease. Key mechanisms discussed include oxidative stress, protein aggregation, and mitochondrial dysfunction.ConclusionThe findings emphasize the need to understand the mechanisms by which environmental toxicants contribute to neurodegenerative diseases. Early detection and management, including reduced exposure to harmful substances, are vital. Further research is essential for improving screening techniques and developing targeted interventions. Introduction Neurodegenerative disorders involve progressive loss of neurons, glial cells, synapses, and networks [1, 2]. They can be categorized by clinical presentation, anatomical localization, or associated molecular abnormalities [1]. Common neurodegenerative disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Pick's disease, dementia with Lewy bodies, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, motor neuron diseases, multiple system atrophy, and spinocerebellar degeneration [3]. Most of these disorders can be categorized into one of four groups: amyloidosis, tauopathies, α‐synucleinopathy, and TAR DNA‐binding protein 43 (TDP‐43) proteinopathy [1, 4]. Neurodegenerative disorders affect nearly 15% of the global population, and their prevalence is expected to increase significantly over the next two decades [5]. The aging brain plays a significant role in neurodegeneration, making these disorders common among the elderly. Genetics and environmental factors can also influence the type of neurodegeneration one experiences [5, 6]. Alzheimer's disease is more common in females, while Parkinson's disease has a 2 times higher prevalence in males. However, the disease progression is higher in females with Parkinson's than in males. Additionally, males are more prone to develop rapid eye movement (REM) sleep behavior and motor abnormalities associated with Parkinson's disease [7]. Neurodegenerative disorders are associated with a decline in memory, executive functioning, cognition, and motor skills, eventually leading to a loss of ability to carry out daily activities and a lifetime of dependency. As a result, these disorders have a debilitating effect on the personal, social, and professional lives of patients [8]. Most of these disorders currently have no cure, so treatment mainly focuses on managing the symptoms and enhancing the quality of life [9]. Therefore, research aimed at identifying the possible predisposing/risk factors is necessary to intervene in neurodegeneration at an early pre‐pathogenesis phase and reduce the disease burden on the population. Humans are constantly exposed to various hazardous man‐made and natural environmental toxicants daily [10]. Industries, automobile emissions, natural disasters, power plants, biological contaminants, tobacco smoking, and heavy metal contamination have increased the environmental toxicant burden [11, 12]. Environmental toxicants are known to have a detrimental effect on the health and function of the brain [13, 14]. They are known to affect the structural and functional integrity of neurons and glial cells through oxidative damage or inflammation by increasing the production of pro‐inflammatory cytokines [13, 15]. Furthermore, environmental toxicants influence epigenetic changes, which modify the disease risk and progression by regulating the immune response and neuronal development [10, 14]. These toxicants have been known to mediate the pathogenesis of various neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, ALS, and demyelinating diseases like multiple sclerosis [12, 14, 16]. Acute and chronic exposure reflect a measure of the length of exposure and not necessarily the intensity of health effects. Short‐term exposures can cause severe, life‐threatening injuries, depending on the substance, its concentration, and the length of exposure. A relevant paper that addresses this relationship is “Interaction of exposure concentration and duration in determining acute toxic effects of sarin vapor in rats [17].” This study examined the impact of different concentrations and durations of exposure to sarin vapor on lethality in rats. The results illustrated that the concentration‐time product (referred to as Haber's Rule) was not a constant over time, so that both individually contribute to toxicity. Interestingly, more concentrated exposures for brief periods may have severe toxic effects, highlighting the fact that acute exposures can have serious health consequences. In this review, we aim to critically analyze the existing literature on the effect of chemical toxicants and air pollutants on the development and progression of neurodegenerative diseases. The review will provide comprehensive knowledge of the variety of toxicants and the mechanisms of neurodegeneration induced by them. Additionally, we will explore possible recommendations to shape future studies on this topic. Methods PubMed was searched for all available data until April 2024. The search strategy included the following keywords: environmental toxicants, neurodegenerative disorders, Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, ALS, multiple sclerosis, MS, Lewy body dementia, Organophosphates, heavy metals, pesticides, solvents, and neurotoxicity. The search was limited to published articles in the English language. Inclusion criteria were as follows: (1) Peer‐Reviewed Articles and (2) Human studies investigating the association between environmental toxicants and neurodegenerative disorders. Exclusion criteria were as follows: (1) articles not in the English language, (2) conference abstracts, editorials, and opinion pieces. Data were extracted for the studies included in the literature review, including study ID, neurodegenerative disorder, neurotoxicant, and possible mechanisms. No tools were used for quality analysis of the included studies; however, each study was evaluated for the appropriateness and relevance of the study design based on our research question. Priority was given to studies with a rigorous methodology, presented results clearly and completely, and reported negative or non‐significant findings transparently. A narrative synthesis of the data was carried out based on the type of neurodegenerative disorder, evidence on specific toxicants, and potential mechanisms of action for each toxicant. Neurotoxicants and Their Pathophysiology in Neurodegenerative Disorders The study of harmful effects on the neurological system brought on by exposure to artificial and natural chemicals is known as neurotoxicology. Some of the earliest recorded documents of human history have a fundamental awareness that some chemicals can impact how the nervous system functions. Documented facts from the first century A.D. and the second century B.C., respectively, describe “lead makes the mind give way” and “gleaming, deadly white lead” by Nero's physician Dioscorides and Nicander, the Greek physician [16, 18]. Neurotoxicants do not have a widely accepted system of classification and may be classified according to a number of properties, such as chemical structure, physical and chemical properties, or clinical effects. Broadly, they can be classified into organic compounds and inorganic compounds, with compounds such as heavy metals and warfare agents included in either group, depending on their chemical nature. For example, the paper “Mechanism of Neurotoxicity” elaborates on how neurotoxic agents can be divided based on their cellular target sites, neuropathologic effects, or by mode of action, underlining the variability in classification systems [19]. Among organic compounds, polychlorinated biphenyls (PCBs) and fluorinated organic substances are notably recognized for their neurotoxic effects [20]. Heavy metals like copper, zinc, iron, arsenic, mercury, and lead have been linked to various neurodegenerative disorders [21]. Sarin, a warfare agent, has been associated with neurogenetic disorders in both in vitro and human studies [22]. Air pollutants such as particulate matter, ozone, and sulfur dioxide are also connected to neurodegenerative diseases. Pathophysiology Inhibition of mitochondrial function, abnormal protein aggregation, excessive oxidative stress that causes neuroinflammation, and the encouragement of apoptosis and neuronal cell death are the common pathophysiology of environmental neurotoxicity (Figure 1) [18]. Parkinson's and Alzheimer's disease have been linked to several neurotoxic metals, including mercury (Hg), manganese (Mn), and arsenic (As), as well as metal‐based nanoparticles and pesticides [12]. Common pathways via chemical toxicants and air pollutants cause neurodegenerative disorders (created with biorender.com & Flaticon.com). According to a recent assessment of research on humans and animals, chronic organophosphate neurotoxicity is partly caused by oxidative stress [23]. Lead alters the brain and behavior through intricate and little‐understood pathways. Since calcium is an essential ion for brain function, including cell development and differentiation, neurotransmitter release, and intracellular metabolic cascades, the effects of lead on these processes are particularly significant [24]. Disruption of the Blood–Brain Barrier (BBB) Certain neurotoxicants are more likely to cross the blood–brain barrier (BBB) by their chemical nature. Highly lipid‐soluble molecules can go across the BBB by simple diffusion, entering the brain. On the other hand, toxicants that resemble endogenous substances can cross the BBB by employing transporters meant for these endogenous molecules [16]. For example, due to structural correspondence with amino acids, the dopaminergic neurotoxicant paraquat can gain access to the brain via the neutral amino acid carrier [23]. Although it is suggested that BBB dysfunction is present in many neurodegenerative diseases, it is yet to be determined whether it contributes to the pathogenesis of the disease or is a result of it [16]. The most likely mechanism causing BBB disruption is inflammation. BBB dysfunction is seen in a multitude of neurodegenerative conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis [24]. In Alzheimer's disease, amyloid β (Aβ) plaques accumulate due to reduced metabolism of amyloid protein within the brain. This causes inflammation, which increases the permeability of the BBB. As a result, neurotoxic molecules can enter the brain and increase Aβ plaque formation [25]. BBB disruption is involved in the pathogenesis of Parkinson's disease. Studies have found a link between polymorphism of the P‐glycoprotein of the BBB and the risk of acquiring PD. However, the risk with the mutation alone was insignificant, but those with the mutation and pesticide exposure exhibited significantly higher risk [26]. BBB dysfunction has also been implicated in multiple sclerosis. Autoimmune CD4 + T lymphocytes cross the BBB, thereby increasing the passive permeability of the BBB to neurotoxicants that can now access the brain and potentiate the disease process [27]. Oxidative Stress Free radicals are constantly generated during the metabolism of endogenous and exogenous substances. They cause damage to lipids, proteins, and DNA. The body encounters them simultaneously through many defense mechanisms, like antioxidant compounds and antioxidant enzymes. Antioxidant compounds include glutathione, arginine, selenium, vitamin E, zinc, and vitamin C, among others, while antioxidant enzymes are catalase, superoxide dismutase, peroxidase, glutathione reductase, and glutathione peroxidase [15]. A growing body of evidence incriminates oxidative stress in the pathogenesis of many neurodegenerative diseases. Substantial evidence suggests that oxidative damage to lipids, proteins, and nucleic acids is found in the brain in many conditions. Animal studies have shown that oxidative stress is the earliest detectable change in the pathogenesis of Alzheimer's disease, preceding amyloid plaque formation. This is contrary to the previous hypothesis that amyloid plaques induce oxidative stress. It is now believed that Aβ peptides initially have an antioxidant role and counteract oxidative stress; they later aggregate, deposit, and transition to pro‐oxidant compounds [15]. ALS occurs in both sporadic and familial forms. Four genes have been identified to be responsible for the familial forms. The gene encoding for cytosolic copper‐zinc superoxide dismutase protein (SOD1) accounts for 20% of the familial forms. It scavenges free radicals produced by mitochondrial respiration. Mutant SOD1 predisposes the DNA to oxidative damage in ALS [28]. According to studies, human Parkinson's disease patients showed an increase in total iron content in the substantia nigra, superoxide dismutase, lipid peroxidation, protein oxidation, and DNA oxidation when compared to controls. Suggesting that neurotoxicants cause Parkinson's disease ultimately to do so by ultimately causing oxidative stress. For example, rotenone and MPTP inhibit mitochondrial complex‐1 and incite oxidative damage [28]. Oxidative stress remains the central theme of research in neurodegenerative diseases, and there is an ongoing quest for antioxidant therapies. Protein Aggregation Protein aggregation and mitochondrial dysfunction are the commonalities of almost all neurodegenerative disorders. As a part of the Protein Quality Control system (PQC), molecular chaperones suppress the misfolding and aggregation of proteins. It also protects it from cellular stress and promotes refolding. Heat shock proteins (HSPs) also inhibit aggregation and promote marking of misfolded proteins [29]. These homeostatic measures are regarded as “proteosis.” Aging promotes aggregation and misfolding of proteins due to the lower capability of chaperones and proteasome activity. It has also been found that CLIPs (chaperone subset) are repressed in the aging of the brain, leading to failure of protection against proteotoxic stress, called “proteostatic collapse” [30]. Protein aggregates can accumulate in cells through two primary mechanisms: (1) Failure of the PQC system, including the UPS. (2) Proteins with intrinsically disordered regions (IDRs) that escape classical folding mechanisms (Figure 2). Protein aggregation occurs during the lifetime of every cell, but it is kept in check by a system called PQC, which is characterized by components such as molecular chaperones and proteolytic systems, which include UPS and autophagy. If PQC fails to function well, these aggregates of misfolded protein accumulate to alarming levels and cause several neurodegenerative disorders [29]. Proteins, when folding, assume a conformation that lowers the system's free energy, resulting in stabilization, which is aided by molecular chaperones. However, proteins with intrinsically disordered regions (IDRs) refuse this aid and escape classical folding, resulting in a metastable state. They are regarded as intrinsically disordered proteins (IDPs). IDRs contain low complexity domains (LCDs), which, in case of any conformational change, lead to an unstable β‐sheet‐enriched intermediate, which forms a proteinaceous aggregate to achieve stabilization [31]. These aggregates can also lead to extracellular or intracellular inclusions. Proteins that are bound to these aggregate‐prone proteins suffer from a loss of function, while aggregation‐prone proteins suffer from a gain of function and interact with other cellular components, resulting in cell damage [30, 32]. Overview of pathways of protein aggregates and their effects leading to neurodegenerative disorders (created with biorender.com). Mechanisms of some neurodegenerative disorders, inclusive of Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, are given below. Parkinson's disease is characterized by intracellular aggregations of α‐synuclein in a ubiquitinated form called Lewy bodies (LB), mainly in substantia nigra, commonly occurring in old age. LB contains various components of PQC, indicating efforts for proteosis [29]. Since neurons cannot dilute toxic material by mitosis, they are extremely sensitive to any sort of aggregation. α‐synuclein is an IDP that helps regulate synaptic vesicle homeostasis and neurotransmitter release by increasing local calcium release. However, its aggregates hinder mitochondrial protein import. The subset of neurodegenerative disorders with the presence of α‐synuclein aggregates is called synucleinopathies [31]. In Alzheimer's disease, there are two types of aggregations, extracellular amyloid‐β and intracellular tau protein in neurofibrillary tangles. Huntingtin protein with long polyglutamine (polyQ) aggregates in Huntington's disease. In ALS, aggregates of superoxide dismutase 1(SOD1) and TAR‐DNA‐binding protein 43(TDP‐43) are present. TDP aggregates are also present in Alzheimer's disease, Huntington's disease, and Parkinson's disease. It plays an important role in regulating synapse‐related genes but can also cause mitochondrial dysfunction by impeding the translation of mitochondrial genes. Since SOD1 is present in mitochondria, it also impacts homeostasis in mitochondria and hinders the apoptotic pathway by binding to the anti‐apoptotic and mitochondrial‐associated protein Bcl‐2 in case of mutation [32]. Various pollutants, as already discussed, like heavy metals, pesticides, air pollutants, and other environmental toxicants, contribute to the development of neurodegenerative disorders. In neurodegenerative diseases, especially Parkinson's disease, pesticides like paraquat and rotenone have been linked to protein aggregation. Paraquat is known to induce oxidative and mitochondrial damage, which encourages α‐synuclein aggregation and neurotoxicity, while rotenone inhibits mitochondrial complex I, which results in a higher generation of reactive oxygen species (ROS), which worsens α‐synuclein misfolding and aggregation [33]. Lead, mercury, and cadmium are examples of heavy metals that interfere with protein homeostasis. Exposure to lead raises tau phosphorylation, which is connected to the pathophysiology of Alzheimer's disease [34]. Mercury increases neurotoxic protein aggregation by interfering with chaperone‐mediated protein folding. Protein misfolding is caused by cadmium's alteration of redox balance and impairment of proteasomal degradation. According to these results, exposure to heavy metals may exacerbate neurodegenerative illnesses by interfering with proteostasis, which preserves the stability of protein aggregation [35]. Environmental toxicants affect protein aggregation through a variety of intricately linked pathways. Numerous toxicants encourage oxidative stress, which damages proteins and lipids, as well as other cellular macromolecules, causing structural instability and misfolding. Aggregate formation is further exacerbated by mitochondrial dysfunction brought on by heavy metals and pesticides, which interfere with energy metabolism and protein clearance pathways. The buildup of harmful protein species is made worse by chronic neuroinflammation, which is frequently brought on by air pollution and heavy metals. Additionally, it has been discovered that toxicants hinder autophagic and proteasomal degradation, two crucial processes for removing misfolded proteins [35]. Air pollution is now widely recognized as a major environmental risk factor for neurological conditions, including Alzheimer's disease (AD) and Parkinson's disease. Increased risks of protein aggregation have also been linked to air pollution, including fine particulate matter (PM2.5) and diesel exhaust particles [36]. Fine particulate matter (PM2.5), which consists of particles smaller than 2.5 µm in diameter, has been extensively researched for its negative effects on brain health. Epidemiological studies have identified an association between long‐term PM2.5 exposure and an increased risk of cognitive deterioration and dementia. A meta‐analysis of 49 studies reported a significant association between extended PM2.5 exposure and all‐cause dementia, AD, and Parkinson's disease, with pooled odds ratios of 1.30, 1.65, and 1.17, respectively [37]. The processes that underlie these correlations are diverse. Inhaled PM2.5 particles can travel to the brain via the olfactory bulb, causing neuroinflammation and oxidative stress, both of which play important roles in the development of neurodegenerative disorders. Air pollution has been linked to increased expression of neurodegenerative disease markers such as alpha‐synuclein and beta‐amyloid, implying a direct role in the etiology of illnesses such as Alzheimer's disease and Parkinson's disease [38]. Motor vehicle exhaust‐related air pollution, a significant source of PM2.5, has been linked to the development of neurodegenerative disorders. Given its prevalence, understanding the role of this source of air pollution is critical, particularly among vulnerable groups. Data suggest that exposure to such pollution may contribute to the onset and progression of dementia, Alzheimer's, and Parkinson's disease [38]. Furthermore, studies have shown that air pollution can cause developmental neurotoxicity, which may contribute to the genesis of neurodevelopmental diseases such as autism spectrum disorder. This demonstrates the larger influence of air pollution on the neurological system at various stages of life [39]. Hence, Air pollution, particularly PM2.5, plays a significant role in the development and progression of neurodegenerative diseases. Addressing air quality issues and reducing exposure to harmful pollutants are critical strategies for mitigating the global burden of conditions like Alzheimer's and Parkinson's. Mitochondrial Dysfunction Mitochondria, despite being lower in number in neurons, are critical to the brain, as the brain consumes 10 times more oxygen and glucose than other tissues in the body [40]. Protein aggregates can directly impact mitochondria through protein–protein interactions (PPI) by interacting with mitochondrial proteins, resulting in mitochondrial dysfunction [32]. Dysfunctional mitochondria are selectively removed by the specific autophagic process called mitophagy. The production of mitochondria is controlled by PGC families, sirtuins and AMP‐activated protein kinases. In neurodegenerative disorders, a 30% increase in expression of PGC‐1a is seen [41]. The fact that the brain is more prone to bioenergetics failure, has fewer antioxidants, and has terminal cells makes it very vulnerable to any change in mitochondrial morphology. Hence, neurodegenerative disorders are characterized by mitochondrial dysfunction, failure of proteoses, and mitophagy [40]. In Parkinson's disease, there is a depression activity of complex 1 of the respiratory chain. It can be caused simply by aging due to the failure of compensatory mechanisms or environmental toxicants like pesticides. An anti‐Parkinson's drug was found to alter the process of terminal oxidation activity in rodents. In Alzheimer's disease, there is a reduction in complexes 1, 4, and 5 and PDHC activity, especially in the frontal cortex. In the case of Huntington's disease, there is oxidative stress due to improper HSF1, which inhibits mitochondrial biogenesis. The huntingtin protein causes MPT opening, which results in the release of cytochrome c, causing apoptosis. It also interferes with the dynactin complex during refolding, resulting in the formation of toxic fragments, especially in mitochondria, and activating caspase. A perinuclear aggregate might be formed as well [40]. TDP causes mitochondrial gene impairment in ALS, and mutant SOD1 binds to anti‐apoptotic bodies since it resides in mitochondria, leading to mitochondrial oxidative damage [32]. Lipofuscin is a pigment that results in reactive oxygen species (ROS) formation. It points toward the aging of the cell. Lipofuscin accumulation interferes with mitophagy by impairing the fusion of autophagosomes and lysosomes, interfering with signaling pathways, and causing oxidative damage. Accumulation of reactive iron species can cause lipid peroxidation, resulting in further oxidative damage and loss of integrity of mitochondria [40]. Neuroinflammation is the result commonly brought about by ROS. They might also interfere with the calcium handling of cells, leading to increased calcium levels, causing a change in mitochondrial potential and production of superoxide ion radicals. High calcium levels can also open mitochondrial permeability transition pores, activating pro‐apoptotic proteins. There is a loss of efficiency of mitochondria associated with ROS [42]. For therapeutic needs, in the case of NDs with severe protein aggregations, we can proceed by targeting the aggregates, chaperones, and degradation systems, promoting extracellular clearance, and finally maintaining the proteostatic machinery of the cell [30]. Therapeutic drugs such as Urolithin A can be given to induce mitophagy to combat the inefficiency of mitochondria, while SIRT1 agonists can be used to activate the other two regulators of mitochondrial biogenesis. Calorie restriction and increasing physical activity have been seen to regulate mitophagy, fight ROS, and slow down transcriptional changes in DNA associated with aging [42]. In conclusion, protein aggregation and mitochondrial dysfunction provide valuable insight into understanding the pathophysiology of neurodegenerative disorders through their synergistic relation. Despite the presence of a wealth of research on this topic, there is still a need for further research in the pathophysiology of these disorders so we can translate the findings into clinical therapies. Potential Mediating Factors Children are highly susceptible to chemical pollutants through direct and indirect exposure, with infants additionally at risk from hand‐to‐mouth contact, enabling ingestion and dermal absorption. Potential mediating factors include higher food and water intake per body weight, maternal transfer during pregnancy or breastfeeding, and incomplete protection from the placenta and blood–brain barrier, which allows many toxins to cross into fetal circulation. Certain environmental exposures in pregnancy could arrest brain development and increase the risk of ADHD and ASD. Furthermore, Neuroinflammation (including COX‐2 upregulation linked to PM2.5 and benzo[a]pyrene), and early‐life pesticide exposure that can cause progressive substantia nigra damage and increase risk of Parkinsonism [43]. Another study identified trauma, solvent exposure, lead, cardiovascular disease, and diesel exhaust as potential mediating factors for ALS risk [44]. Research shows men are 1.5–2 times more likely to develop Parkinson's disease and are more vulnerable to dopaminergic neurodegeneration from environmental exposures. Some mediating mechanisms include estrogen protection, SRY gene expression, VGLUT2 function, and microbiome differences [45]. A death certificate analysis from the U.S found elevated mortality from presenile dementia, Alzheimer's disease, Parkinson's disease, and motor neuron disease in several occupations, notably teachers, hairdressers, clergy, and non‐horticultural farmers. The findings support occupational exposures, such as pesticides, solvents, oxidative stressors, 60 Hz magnetic fields, and welding fumes [46]. Overall, these findings highlight environmental and occupational exposures as key, preventable drivers of brain disorders. Dose‐Dependent Effects Miners and welders with blood Manganese levels > 15 μg/L develop a specific, l‐DOPA–resistant Parkinsonism, implying a threshold above which toxicity is likely. Similar patterns are seen with cobalt, where toxicity aligns with elevated blood and urine levels. A review conducted on cadmium in Alzheimer's disease also supports a positive correlation between higher systemic levels and disease severity. Elevated brain iron, zinc, lead, aluminum, and cadmium in AD or PD cases suggest accumulation correlates with pathology. For some metals, such as zinc, effects appear biphasic as both deficiency and excess may be harmful, so the relationship isn't strictly linear [47]. Low doses can still produce significant neurotoxic effects when exposure is chronic and the toxicant is persistent, because each small exposure incrementally adds to the total body burden. Over months or years, these repeated “microdoses” can reach critical thresholds within target tissues like the brain. So, the dose–response curve is influenced not just by peak exposure but by time‐integrated dose, meaning total accumulation is the key determinant of toxicity [48]. Gene Environment Interactions Gene–environment interactions play a determining role in determining human health outcomes, particularly in neurodegenerative diseases. While familial cases of Parkinson's disease exist due to single‐gene mutations such as LRRK2, most PD cases are sporadic, involving an interplay between susceptibility genes and exposures such as pesticides. Pesticides interaction with genes often involve xenobiotic metabolism genes such as CYP2D6's inability to effectively metabolize certain pesticides shows stronger associations between pesticide exposure and PD [49, 50]. Variants in MDR1 (affecting P‐glycoprotein function at the blood–brain barrier) and the dopamine transporter gene (SLC6A3) may also play a role in pesticide‐induced dopaminergic dysfunction. The ε4 allele of APOE is the major genetic susceptibility factor for late‐onset age disease of Alzheimer's disease [49]. Heavy metals can also interact with genetic variants in SLC30A10 and ATP7B to increase the risk of Parkinson's disease (PD) and cognitive impairment through oxidative stress and mitochondrial dysfunction [50]. Literature Review Table 1 summarizes the existing literature on the association between chemical neurotoxicants and air pollutants with common neurodegenerative disorders. TABLE 1Summary of existing literature on the association between chemical neurotoxins and air pollutants with common neurodegenerative disorders.ReferenceStudy designNeurodegenerative disorderNeurotoxinPossible mechanism & conclusionYong Li Zhao, Yi Qu et al. 2021 [51]Meta‐analysisAll‐cause dementiaParticulate matter (PM2.5) and Nitric Oxide (NO2) Due to their small size, they can easily damage the endothelial cells of the brain, lead to increased free radical production, and induce oxidative stress. Free radical production also destroys structures like mitochondria and causes neuroinflammation and protein aggregation [52]. The meta, however, could find no association between PM2.5 and other neurodegenerative disorders. Gómez‐Anca & Barros‐Dios, 2020 [53]Meta‐analysisMultiple sclerosisRadon gasRadon is a fat‐soluble gas, so it gets absorbed in the nerve myelin sheath and releases α‐particles, which cause irreversible damage to the myelin sheath. Free radicals' generation and radon decay products would lead to potential oxidative damage to neurons due to their lipid‐soluble profile.Pengfei Fu and Ken Kin Lam Yung, 2020 [54]Meta‐analysisAlzheimer's diseaseParticulate matter (PM2.5)The PM‐induced inflammatory process could lead to amyloid accumulation, tau protein phosphorylation, and synaptic dysfunctions contributing to Alzheimer's disease. Moreover, inhalation via the lungs can activate inflammatory responses in the lungs, and the cytokines produced can reach the brain and cause damage.Antonio Cristaldi et al. 2022 [55]Meta‐analysisAlzheimer's disease, Parkinson's disease, and multiple sclerosisParticulate matter (PM2.5)Exposure to PM2.5 fosters neuroinflammation as the inhaled particles can reach the nasal epithelial mucosa and transfer to the brain via the olfactory bulb. Additionally, PM2.5 exposure has been linked to increased expression of neurodegenerative disease markers, such as alpha‐synuclein and beta‐amyloid, potentially contributing to the development of these diseases.Yuting Gong et al. 2023 [56]Meta‐analysisAlzheimer's disease, Parkinson's disease, and multiple sclerosisParticulate matter (PM2.5)This is one of the largest Metas in the domain and suggests a correlation between PM2.5 and most neurodegenerative disorders, unlike other studies, which could find a correlation with only dementia and not with ALS or multiple sclerosis, and so forth.Maria Iosifina et al. 2019 [57]Meta‐analysisParkinson's diseaseAir pollutants (PM2.5, CO, NO2, and O3)The study found a weak association between traffic‐related air pollution and Parkinson's disease.Eirini et al., 2018 [58]Systematic reviewDementiaBC, NOx, NO2, traffic noise, proximity to a major road, and traffic PMThe impact of inhaled particles on the CNS may emerge due to particle translocation (via neurons or blood) to the CNS following inhalation or releasing systemically acting factors from the lung, impacting neuron function.Han et al., 2020 [59]Systematic review and meta‐analysisParkinson's diseaseAir pollution and secondhand smokeAir pollutants like PM2.5, NO2, and O3 increased the risk of Parkinson's disease, whereas Secondhand smoke reduced the risk. One possible explanation is that some tobacco smoke compounds had monoamine oxidase (MAO) inhibitory properties. MAO plays an important role in the bioactivation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), a well‐known Parkinson's disease‐inducing neurotoxin.Dhiman et al., 2022 [41]Systematic review and meta‐analysisAll‐cause dementia, cognitive decline, and Alzheimer's diseasePM2.5 and PM10, ozone (O3), carbon monoxide (CO), nitrogen dioxide (NO2), nitrogen oxides (NOX), and sulfur dioxide (SO2)PM2.5, when inhaled, can reach the brain via the olfactory bulb and induce an inflammatory response and microglial activation and increase the production and deposition of β‐amyloid (Aβ) peptides. Exposure to O3 may generate oxidative stress, which leads to brain lipid peroxidation, changes in neuronal morphology, and memory deterioration.Wang et al., 2020 [60]Systematic review and meta‐analysisParkinson's diseasePM2.5 and PM10 PM2.5 may increase ROS production in vascular endothelial cells. In the human body, subjects exposed to elevated levels of air pollution exhibit great neuronal and extracellular α‐synuclein accumulation in affected neurons.Fu et al., 2019 [61]Systematic review and meta‐analysisAlzheimer's disease and Parkinson's diseasePM2.5 PM2.5 may act as environmental antigens and trigger the development of Alzheimer's disease by promoting the formation of amyloid plaques in the human brain. PM2.5 can incur oxidative stress, inflammation, and altered α‐synuclein aggregation, leading to neuronal injury and the loss of dopaminergic neurons in the substantia nigra, which are possible toxicological mechanisms of the onset and aggravation of Parkinson's disease induced by PM2.5.Oliveira et al., 2020 [62]Systematic reviewMultiple sclerosis, ALS, Parkinson's disease, and Alzheimer's diseasePM, CO, SO2, CO, sunlight, and temperatureUV radiation may be immunosuppressive, leading to multiple sclerosis.Tsai TL et al., 2019 [63]Systematic review and meta‐analysisAlzheimer's diseasePM2.5 Animal models have shown that exposure to fine and ultrafine particulate matter (PM) or diesel exhaust increases the expression of NF‐κB and pro‐inflammatory cytokines (TNF‐α and IL‐1α) in brain regions, particularly the midbrain. A 2002 study in Mexico City reported that long‐term exposure of dogs to urban air pollution (PM and O3) leads to early and persistent NF‐κB activation, iNOS expression, blood–brain barrier alterations, neuronal degeneration, glial cell apoptosis, APOE‐positive lipid droplet deposition, and the development of Alzheimer's‐like plaques and tangles. Exposure to PM2.5 was positively associated with a higher risk for dementia. Further epidemiological studies with well‐validated outcomes and with standardized exposure assessment models are required to ascertain the relationship between PM2.5 and dementia/AD.Allam MF et al., 2002 [64]Systematic reviewParkinson's diseaseSmokingSmoking induces debrisoquine 4‐hydroxylase, which is responsible for the metabolism of antipsychotic drugs and the detoxification of certain environmental toxins known to cause dopaminergic neural damage.Anastasia Bougea et al. 2023 [65]Meta‐analysisParkinson's diseaseAir pollutants (PM2.5, CO, NO2, and O3)A link between air pollutants and temperature in the progression of Parkinson's disease has been suggested, but it remains unproven. Further longitudinal studies are needed to validate these findings.Bombonica Gabriela et al. 2023 [66]Systematic reviewHuntington's, Alzheimer's, and Parkinson's diseaseHydrogen sulfide (H2S)H2S modulates DNA methyltransferases (DNMTs), inhibiting them and decreasing methylation, which leads to altered gene expression, decreasing neuronal survival, causing neuroinflammation, and oxidative stress response.Lilian Calderón‐Garcidueñas et al. 2024 [67]Original researchAlzheimer's disease, Parkinson's disease, Frontotemporal Lobar Degeneration (FTLD), and Amyotrophic Lateral Sclerosis (ALS) Ultrafine Particulate Matter (UFPM, PM2.5, PM10) Industrial & combustion nanoparticles (NPs) of heavy metals: Iron (Fe), Titanium (Ti), Aluminum (Al), Vanadium (V), Nickel (Ni), Mercury (Hg), Cobalt (Co), Copper (Cu), Zinc (Zn), Silver (Ag), Platinum (Pt), Cerium (Ce), Lanthanum (La), Praseodymium (Pr), Tungsten (W)Diesel exhaust and airborne pollutants containing neurotoxic metals Air pollution exposure leads to early‐onset neuropathology, with ultrafine particles and metal nanoparticles entering the brain via the olfactory, respiratory, gastrointestinal, and vascular routes.Qiumei Yang et al. 2024 [68]Experimental studyParkinson's diseaseLipopolysaccharide (LPS)The LRRK2 R1627P mutation contributes to Parkinson's disease pathogenesis by impairing the trans‐Golgi‐lysosomal pathway, leading to dendritic spine degeneration, protein accumulation, and heightened susceptibility to environmental toxins like LPS.John Wiley & Sons, Ltd. Summary of existing literature on the association between chemical neurotoxins and air pollutants with common neurodegenerative disorders. Due to their small size, they can easily damage the endothelial cells of the brain, lead to increased free radical production, and induce oxidative stress. Free radical production also destroys structures like mitochondria and causes neuroinflammation and protein aggregation [52]. The meta, however, could find no association between PM2.5 and other neurodegenerative disorders. Ultrafine Particulate Matter (UFPM, PM2.5, PM10) Industrial & combustion nanoparticles (NPs) of heavy metals: Iron (Fe), Titanium (Ti), Aluminum (Al), Vanadium (V), Nickel (Ni), Mercury (Hg), Cobalt (Co), Copper (Cu), Zinc (Zn), Silver (Ag), Platinum (Pt), Cerium (Ce), Lanthanum (La), Praseodymium (Pr), Tungsten (W)Diesel exhaust and airborne pollutants containing neurotoxic metals Clinical Implications With the increasing advent of neurological symptoms caused by chemical toxicants and air pollutants, it is important to highlight and further development in the field of screening and early diagnosis of neurotoxicity. Screening techniques need to be accurate and accessible to a larger population. Histopathology and clinical evaluation are a mainstay for screening, including motor development, attainment of milestones, and other signs of neurological disorders like seizure, tremors, or weakness [69]. Recent advances in screening techniques include the evolution of multi‐electrode array technology to identify certain target chemicals in neurons. This has been recently tested in 3D neuron models of humans, and the results promise to revolutionize the screening arena [70]. Diagnosis of neurotoxicity mainly relies on the common manifestations such toxicants cause. They often present with altered cognition or sensorimotor symptoms [71]. To obtain a clinching diagnosis, it is important to know about specific toxicity manifestations of certain chemicals. Like screening, diagnosis relies heavily on clinical examination, focusing on the sensory, motor, cranial nerve, and autonomic system examination. Reflexes and cognitive functions can also be targeted as potential tests [72]. While acute exposure or cases with an immediate history of contact with a chemical can help identify the causative chemical, chronically presenting neurotoxicity is harder to interpret [73]. Exposure can be ascertained by certain biochemical tests specific to the suspected chemical. Legrand et al. identified four cornerstones of diagnosis involving hazard characterization, which involves the common manifestation of the toxicant in a general population; effects, describing different specific behavioral, developmental, or endocrine effects; biomarker assays, involving sensory or in vitro assays, and other chemical analyses [74]. The mainstay treatment of environmental neurotoxicity involves reducing or eliminating exposure. Symptomatic treatment in the approach followed as different drugs are administered specifically to the manifestation. There may be an acute presentation of some neurotoxicity in a critical condition, and such cases may necessitate aggressive intravenous fluid replacement or chelating agents to facilitate rapid clearing of the drug [73]. Primary exposure prevention is the goal for managing neurotoxicity by chemicals on a larger scale. Such strategies involve a wide‐scale collaboration between different stakeholders. Policies must be kept in place to reduce the use of harmful chemical compounds and switch to safer alternatives. The Cleaner Production–Pollution Prevention (CPPP) is one such effort undertaken by the US government to grossly reduce exposure and prevent rampant toxicities [75]. Other techniques include routine testing of chemicals before being circulated for use among the masses. Post‐marketing secondary surveillance can also play a great role in the identification of toxic manifestations [76]. There is a need to continue developing newer modalities for detecting and diagnosing chemical toxicants. Recent advances include the integration of machine learning models for better risk prediction [77]. In vitro studies on rats and zebrafish also help detect certain chemicals' neurotoxic potential [78]. For the prevention of such neurodegenerative disorders, antioxidants have proved to be an excellent mechanism that can be divided into three lines of defense. Superoxide dismutase, glutathione reductase and peroxidase, catalase, and minerals, inclusive of selenium, copper, manganese, and zinc, are considered the first line of defense; meanwhile, the second line of defense is Glutathione, vitamins E and C, uric acid, albumin, carotenoids, and flavonoids. Finally, the third line of defense includes antioxidants, a complex group of enzymes for repairing damaged biomolecules, such as protein, DNA, and lipids [79]. Several dietary compounds have also been shown to have an inhibitory effect on cell degeneration associated with neurodegenerative disorders, like polyphenols such as curcumin, resveratrol, ginseng, rosmarinic acid, and other nutritious components, such as propolis, ω−3 polyunsaturated fatty acids (PUFAs). Another strategy that might be helpful is caloric restriction, which lowers oxidative stress in cells [80]. Apart from these strategies, neurodegenerative disorders that result from environmental toxicants demand limiting exposure and early removal of the causative agent once identified. Conclusion Environmental toxicants, such as chemical toxicants and air pollutants, can have a devastating impact on neuronal degeneration. The adverse health effects of environmental toxicants, as seen in Parkinson's disease, Alzheimer's disease, Multiple sclerosis, and Huntington's disease, can have a long‐term deteriorating effect. This review summarizes the existing knowledge about the association between chemical toxicants and air pollutants with neurodegenerative disorders and the assumed underlying pathophysiological mechanisms. Different neurotoxicants have variable effects. However, they commonly lead to oxidative stress, protein aggregation, and mitochondrial dysfunction, which leads to neurodegenerative disease. Recent advancements in screening and diagnosing neurotoxicity emphasize the integration of multi‐electrode array technology for precise chemical identification in neuronal models. Clinical diagnosis relies on recognizing cognitive and sensorimotor symptoms, while treatment focuses on reducing exposure and symptomatic management. Prevention strategies include policy‐driven reductions in harmful chemical use and the integration of antioxidant therapies to mitigate neurodegenerative effects. Author Contributions Sameeha Fatima Khan: conceptualization, writing – original draft, writing – review and editing. Warda Rasool: writing – original draft, writing – review and editing. Muhammad Hamza Khan: conceptualization, writing – original draft, writing – review and editing, visualization. Ganesh Kumar: conceptualization, writing – original draft, writing – review and editing. Azka Ijaz: writing – original draft, writing – review and editing. Maryam Amjad: conceptualization, writing – original draft, writing – review and editing. Mahin Qudeer Sheikh: writing – original draft, writing – review and editing. Shree Rath: conceptualization, writing – original draft, writing – review and editing. Digbijay Kunwar: writing – original draft, writing – review and editing. Anum Akbar: conceptualization, writing – original draft, writing – review and editing, visualization, supervision. Funding The authors have nothing to report. Disclosure The lead author Digbijay Kunwar affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Conflicts of Interest The authors declare no conflicts of interest.